Aggregatibacter actinomycetemcomitans

From WikiMD's WELLNESSPEDIA

Aggregatibacter actinomycetemcomitans is a Gram-negative, facultative anaerobic bacterium that is a member of the HACEK group. It is primarily associated with periodontal diseases, and is also implicated in non-oral infections such as endocarditis and other systemic diseases.

Characteristics[edit]

Aggregatibacter actinomycetemcomitans is a small, non-motile, coccobacillary bacterium. It is oxidase positive and can ferment a variety of sugars to produce acid. The bacterium is also capable of producing a leukotoxin that is harmful to human immune cells.

Pathogenesis[edit]

Aggregatibacter actinomycetemcomitans is a significant pathogen in periodontal disease. It is particularly associated with localized aggressive periodontitis, a severe form of gum disease that occurs in adolescents and young adults. The bacterium adheres to oral surfaces and forms biofilms, which contribute to plaque formation and gum inflammation.

In addition to its role in oral disease, Aggregatibacter actinomycetemcomitans can also cause non-oral infections. It is one of the HACEK organisms, a group of Gram-negative bacteria that are a rare cause of endocarditis, an inflammation of the heart valves.

Treatment[edit]

Treatment of infections caused by Aggregatibacter actinomycetemcomitans typically involves antibiotics. The bacterium is usually sensitive to tetracycline, amoxicillin, and clindamycin. In cases of periodontal disease, treatment may also include mechanical cleaning of the teeth and gums to remove plaque and tartar.

See also[edit]

References[edit]


Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.